ABCC1

Multidrug resistance-associated protein 1 · P33527 · ABCC1 on Sugi Atlas →

71,294 patent compounds predicted against ABCC1, 44,443 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL392277	0.59	10/20
Hexobendine (SCHEMBL125629)	0.69	9/20
Hexobendine (SCHEMBL317378)	0.68	9/20
Furoxan (SCHEMBL320190)	1.00	8/20
SCHEMBL390057	0.75	7/20
SCHEMBL389903	0.59	6/20
SCHEMBL391608	0.57	6/20
SCHEMBL391607	0.56	6/20
Butobendine (SCHEMBL309587)	0.47	6/20
SCHEMBL390423	0.58	5/20
SCHEMBL326797	0.56	5/20
Verapamil (SCHEMBL16742)	1.00	4/20
Myricetin (SCHEMBL19302)	1.00	4/20
Dexverapamil (SCHEMBL33297)	1.00	4/20
Verlukast (SCHEMBL37246)	1.00	4/20
Verlukast (SCHEMBL37247)	1.00	4/20
Verlukast (SCHEMBL156453)	1.00	4/20
Mk-571 (SCHEMBL156452)	0.98	4/20
Verlukast (SCHEMBL156454)	0.98	4/20
Verapamil (SCHEMBL33296)	0.98	4/20

Clinical trials — most relevant to ABCC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin	PHASE2/PHASE3	UNKNOWN
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer	PHASE2	UNKNOWN
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer	PHASE2	COMPLETED
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	PHASE2	COMPLETED
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer	PHASE2	COMPLETED
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Influence of Ethnicity and ABCB1 Gene Polymorphism on the Pharmacokinetics of Azithromycin in Healthy Bangladeshi Volunteers	PHASE1	UNKNOWN
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas	PHASE1	COMPLETED
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer	PHASE1	COMPLETED
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas	PHASE1	COMPLETED
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors	PHASE1	COMPLETED
the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin	nan	UNKNOWN
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia	nan	ACTIVE_NOT_RECRUITING
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients	nan	UNKNOWN
Collection of Tissue Samples for Study of Multidrug Resistance	nan	COMPLETED
Transplacental Transfer of Drugs Used in Pregnant Women	nan	COMPLETED
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Role of the ATP7A Transporter in Ovarian Cancer	nan	COMPLETED
Pharmacogenetics in Non Small Cell Lung Cancer	nan	UNKNOWN
Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia	nan	COMPLETED
A Prospective Study on Effect of Systemic Adjuvant Therapy on Cognitive and Brain Function of Breast Cancer Patients	nan	UNKNOWN
Pharmacogenetics Study in Taiwan's Ethnic Groups	nan	COMPLETED
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720	nan	COMPLETED
Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial	nan	COMPLETED
Role of Gene Variation in Effectiveness of Gleevec Treatment	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ABCC1 binder may also engage these)

Protein	Name	Similarity
O35379	—	1.000	O35379 →
Q8HXQ5	—	1.000	Q8HXQ5 →
Q864R9	—	1.000	Q864R9 →
Q6UR05	—	0.999	Q6UR05 →
Q8CG09	—	0.997	Q8CG09 →
Q5F364	—	0.995	Q5F364 →
B2RX12	—	0.995	B2RX12 →
Q9C8G9	—	0.994	Q9C8G9 →
ABCC8	ATP-binding cassette sub-family C member 8	0.990	landscape →
Q09429	—	0.990	Q09429 →
Q63120	—	0.990	Q63120 →
O88563	—	0.989	O88563 →
ABCC3	ATP-binding cassette sub-family C member 3	0.988	landscape →
Q42093	—	0.988	Q42093 →
Q8VI47	—	0.988	Q8VI47 →
Q09427	—	0.988	Q09427 →
F1M3J4	—	0.987	F1M3J4 →
Q9C8H0	—	0.987	Q9C8H0 →
Q9U2G5	—	0.987	Q9U2G5 →
Q8LGU1	—	0.985	Q8LGU1 →
P91660	—	0.985	P91660 →
Q28689	—	0.985	Q28689 →
Q9C8H1	—	0.985	Q9C8H1 →
A2XCD4	—	0.985	A2XCD4 →
Q9QYM0	—	0.985	Q9QYM0 →
Q9SKX0	—	0.984	Q9SKX0 →
Q9R1X5	—	0.984	Q9R1X5 →
Q9JJ59	—	0.984	Q9JJ59 →
Q9M1C7	—	0.984	Q9M1C7 →
ABCC2	ATP-binding cassette sub-family C member 2	0.983	landscape →